CPI-006 was investigated in clinical trials NCT03454451, NCT04464395, and NCT04734873 to evaluate its safety and efficacy. NCT03454451 focused on advanced cancers (e.g., non-small cell lung cancer, renal cell cancer, colorectal... NCT04464395 and NCT04734873 assessed its use for hospitalized COVID-19 patients alone or with standard care.
- Mechanism
- Curator reviewed
CPI-006 is a humanized monoclonal antibody which binds to the CD73 cell-surface ectonucleotidase and causes activation of B cells and production of antibodies. It is an immunomodulatory compound currently being investigated against the SARS-CoV-2 virus.
- Also known as
- IMMUNOGLOBULIN G1 (302-GLUTAMINE), ANTI-(HUMAN 5'-NUCLEOTIDASE) (HUMAN-MUS MUSCULUS MONOCLONAL CPI-006 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS-MUSCULUS MONOCLONAL CPI-006 .KAPPA.-CHAIN, DIMER
- Code names
- CPI-006 · CPX-006
Resolves to
What you can answer from here — as of July 08, 2026
Which drugs share a target with Mupadolimab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account